Detalles de la búsqueda
1.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34758069
2.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38693677
3.
The complex intervention day hospice - a quality-assured study on the implementation, realization, and benefits with model character for Germany (IMPULS) using the example of "Day hospice Adiuvantes".
BMC Palliat Care
; 23(1): 18, 2024 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229069
4.
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Int J Cancer
; 153(6): 1227-1240, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260368
5.
Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care.
J Cancer Educ
; 37(1): 120-127, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32588349
6.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
7.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107341
8.
[Onko-Nexus: A Bavarian "Caretaker Project" to Overcome the Interface Outpatient/Hospitalized Division - Three-Year Results]. / Onko-Nexus: Ein bayerisches "Kümmererprojekt" zur Überwindung der Schnittstelle ambulanter/stationärer Sektor die drei Jahresergebnisse.
Gesundheitswesen
; 83(6): 450-456, 2021 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-32259869
9.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
BMC Cancer
; 20(1): 286, 2020 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252684
10.
Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis.
BMC Palliat Care
; 19(1): 140, 2020 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919468
11.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047142
12.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032641
13.
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Anticancer Drugs
; 28(7): 717-722, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28582279
14.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575024
15.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 17(7): 928-942, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216274
16.
[Correction: Onko-Nexus: A Bavarian "Caretaker Project" to Overcome the Interface Outpatient/Hospitalized Division - Three-Year Results]. / Erratum: Onko-Nexus: Ein bayerisches "Kümmererprojekt" zur Überwindung der Schnittstelle ambulanter/stationärer Sektor die drei Jahresergebnisse.
Gesundheitswesen
; 83(6): e39, 2021 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-32746475
17.
[Four years of specialized outpatient palliative care in a rural area : Cooperation and acceptability from general practitioners' view]. / Vier Jahre spezialisierte ambulante Palliativversorgung (SAPV) im ländlichen Bereich : Zusammenarbeit und Akzeptanz aus hausärztlicher Sicht.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
; 59(7): 916-20, 2016 Jul.
Artículo
en Alemán
| MEDLINE | ID: mdl-27273302
18.
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Int J Cancer
; 137(3): 678-85, 2015 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25530271
19.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Acta Oncol
; 54(7): 993-1000, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25924969
20.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940